Scientist » Dr. Mohankumar K. Murugesan

Mohankumar K. Murugesan  

Contact

Centre for Stem Cell Research
Christian Medical College

Office: +91 416 307-5140
Lab: +91 416 307-5139
Fax: +91 416 307-5103
Email: mohankumarkm@cmcvellore.ac.in

Career Interests

Genome Editing for Gene and Cell Therapy
Cancer Stem Cells
Tumor modeling using the CRISPR/CAS9 system
Cancer Immunotherapy

Education

  • Post-Doctoral Research Fellow                                                                                     2007-2015
    St. Jude Children’s Research Hospital, Memphis, TN, USA.
  • PhD in Molecular Medicine (Breast Cancer Biology)                                               2004- 2007
    Liggins Institute, University of Auckland, Auckland, New Zealand.
  • MSc in Medical Biochemistry                                                                                         1997-2000
    JIPMER, Pondicherry, India.

Awards

  • Kelliher Trust Award for Research Innovation.
  • International Doctoral Scholarship, University of Auckland, New Zealand.
  • Maurice and Paykel Trust Grant.
.

Research

My laboratory is interested in developing innovative therapeutic genome editing tools to treat patients with inherited hematological disorders such as sickle cell diseases and thalassemia. We are planning to directly manipulate the genome of human hematopoietic stem cells (HSCs) in a sequence specific manner using targeted genome engineering platform based on CRISPR/CAS9 system for the treatment of inherited hematological disorders. We are further working on the delivery platforms to increase the genome editing efficiency and reduce the off target effects. We anticipate that our strategy will overcome the therapeutic barriers that currently limit the clinical applications.

Research Fellows

Bhanu Prasad Bandlamudi

Bhanu Prasad Bandlamudi

Junior Research Fellow
E-mail: bhanu.bandlamudi@cmcvellore.ac.in
Research Interests:
Education: MSc., Biochemistry

Bhanu Prasad Bandlamudi

Rachel Anand Nethala

Junior Research Fellow
E-mail:rachel.anand@cmcvellore.ac.in
Research Interests:
Education: MSc.,Regenerative Medicine

Technical Staff

 

 

 

Selected Publications

  • Mohankumar KM, Currle DS, White E, Boulos N, Dapper J,Eden C, Nimmervoll B, Thiruvenkatam R, Connelly M, Kranenburg TA, Neale G, Olsen S, Wang M, Finkelstein D, Wright K, Gupta K, Ellison DW, Thomas AO, Gilbertson RJ. In vivo oncogenomics screen identifies novel ependymoma oncogenes and tumor suppressors within large    chromosomal alterations   Nature Genetics. 47:878-87, 2015.
  • Matthew Parker*, Mohankumar KM*, Punchihewa C *, Weinlich R*, Dalton JD, Lee R, Ruth G, Tatevossian RG,. Phoenix TN, Thiruvenkatam R, Li Y, White E, Tang B, Orisme W, Gupta K, Rusch M, Chen X, Nagahawhatte P, Hedlund E, Finkelstein D, Wu G, Shurtleff S, Easton J, Boggs K, Yergeau D, Vadodaria B, Mulder HL, Becksford J, Gupta P, Huether R, Ma J, Song G, Ding L, Lu C, Ochoa K, Zhao D, Fulton RS, Fulton LL, Mardis ER, Wilson RK, Downing JR, Green D, Zhang J, Ellison DW, and Gilbertson RJ. Highly recurrent C11ORF95 fusions drive oncogenic NF-?B signaling in Ependymoma. Nature. 500:451-455, 2014. *equal contribution.
  • Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB, Rand V, Leary SE, White E, Eden C, Hogg T, Northcott P, Mack S, Neale G, Wang YD, Coyle B, Atkinson J, DeWire M, Kranenburg TA, Gillespie Y, Allen JC, Merchant T, Hoop FA, Sanford RA, Gajjar A, Ellison DW, Taylor MD, Grundy RG, Gilbertson RJ. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature. 466:632-6, 2010.
  • Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell. 20:384-99, 2011.
  • Mohankumar KM, Xu XQ, Zhu T, Kannan N, Miller L, Liu ET, Gluckman PD, Sukumar S, Emerald BS, Lobie PE. HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. Oncogene. 26: 3998-4008, 2007.
  • Eden CJ, Ju B, Mohankumar KM, Phoenix T, Nimmervoll B, Tong Y, Ellison DW, Lessman C, Taylor MR, Gilbertson RJ. Orthotopic models of pediatric brain tumors in zebrafish. Oncogene. 2015 Mar 26;34(13):1736-42, 2014.
  • Mohankumar KM, Perry JK, Kannan N, Kohno K, Gluckman PD, Emerald BS, Lobie PE. Transcriptional activation of STAT3 and STAT5B is important for HOXA1 mediated oncogenic transformation of immortalized human mammary epithelial cells. Endocrinology.149: 2219-29, 2008.
  • Evseenko DA, Murthi P, Paxton JW, Reid G, Emerald BS, Mohankumar KM, Lobie PE, Brennecke SP, Kalionis B, Keelan JA. The ABC transporter BCRP/ABCG2 is a Placental survival factor and its expression is reduced in idiopathic human fetal growth restriction. FASEB J. 21:3592-605, 2007.
  • Pandey V, Perry JK, Mohankumar KM, Kong XJ, Liu SM, Wu ZS, Mitchell MD, Zhu T, Lobie PE. Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology.149:3909-19, 2008.
  • Zhang X, Emerald BS, Mukhina S, Mohankumar KM, Kraemer A, Yap AS, Gluckman PD, Lee KO, Lobie PE. HOXA1 is required for E-cadherin dependent anchorage independent survival of human mammary carcinoma cells. J Biol Chem 281: 6471-81, 2006.
  • Ramakrishna L, Anand KK, Mohankumar KM, Ranga U. Codon optimization of the Tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol 78: 9174-89, 2004.
  • Hou L, Xu B, Mohankumar KM, Goffin V, Perry JK, Lobie PE, Liu DX. The prolactin receptor mediates HOXA1- stimulated oncogenicity of mammary carcinoma cells. Int J Oncol. 41:2285-95, 2012.
  • Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, Grandison PM, Liu DX, Lobie PE. Trefoil factor 3 is Oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia.12:1041-53, 2010.
  • Ramakrishna L, Anand K, Mahalingam M, Mohankumar KM, Ramani S, Siddappa NB, Ranga U. Codon optimization and ubiquitin conjugation of HIV-1 Tat lead to enhanced cell mediated immune responses. Vaccine 22: 2586-98, 2004.
  • Mohankumar KM, Bobby Z, Selvaraj N, Das A, Koner BC, Sen SK, Ramesh R, Ranganathan P. Possible link between glycated hemoglobin and lipid peroxidation in hyperthyroidism. Clinical Chemistry Acta 342: 187-192, 2004.
  • Perry JK, Mohankumar KM, Emerald BS, Mertani HC, Lobie PE. The contribution of growth hormone to mammary neoplasia. J Mammary Gland Biol Neoplasia.13:131- 45, 2008. (Review).

Group Photo Lab 9

 



"Contents will be updated soon."



"Contents will be updated soon."